A recurrence of C. diff is common after an initial episode, with about 20% of people having a recurrence. A recurrence is ...

Clostridioides difficile (C. difficile) infection (CDI) is a significant healthcare-associated infection, known for its high morbidity and mortality rates, especially in vulnerable populations. CDI ...

I am 78 years old and in fair health.

A novel vaccination approach developed by Vanderbilt Health researchers cleared the harmful gut bacterium Clostridioides ...

Paul Feuerstadt, MD, FACG, AGAF, discusses how testing for Clostridioides difficile is recommended for hospitalized patients or outpatients with new-onset, unexplained diarrhea who have risk factors ...

Incidence rates of health care-associated Clostridioides difficile infection were 3 times higher in patients with COVID-19 than those without coronavirus infection in a Serbian hospital. CDI is a ...

Novel C. diff vaccine shows long-term protection in animal studies, reducing illness, death, and infection recurrence, per Vanderbilt Health research.

As antibiotic resistance grows, so does research toward preventing and treating Clostridioides difficile, a bacterium known to be one of the leading causes of healthcare-associated infections in U.S.

Gastrointestinal tumors remain a global health challenge, with high incidence and mortality. Among them, colorectal cancer (CRC) carries the heaviest burden and serves as a key model for how the gut ...

Recurrent C. diff infection is when you contract a C. diff infection 2 to 8 weeks after completing treatment for a previous one. C. diff relapse is a recurrence of the same strain, while reinfection ...